DprE1 inhibitors – a prospective target for development of antituberculosis drugs
The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with ant...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2022-06-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1644 |
| _version_ | 1826562992749150208 |
|---|---|
| author | A. V. Kukurika |
| author_facet | A. V. Kukurika |
| author_sort | A. V. Kukurika |
| collection | DOAJ |
| description | The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with antituberculosis activity, which requires further clinical trials. |
| first_indexed | 2024-03-12T18:41:48Z |
| format | Article |
| id | doaj.art-74292493297b4ff592f48863a29f2208 |
| institution | Directory Open Access Journal |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| last_indexed | 2025-03-14T09:56:53Z |
| publishDate | 2022-06-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj.art-74292493297b4ff592f48863a29f22082025-03-02T11:22:35ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062022-06-011005647010.21292/2075-1230-2022-100-5-64-701639DprE1 inhibitors – a prospective target for development of antituberculosis drugsA. V. Kukurika0Makeevka Municipal TB DispensaryThe article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with antituberculosis activity, which requires further clinical trials.https://www.tibl-journal.com/jour/article/view/1644dpre1antituberculosis drugsbtz-043pbtz-169tba-7371opc-167832multiple/extensive drug resistant tuberculosis |
| spellingShingle | A. V. Kukurika DprE1 inhibitors – a prospective target for development of antituberculosis drugs Туберкулез и болезни лёгких dpre1 antituberculosis drugs btz-043 pbtz-169 tba-7371 opc-167832 multiple/extensive drug resistant tuberculosis |
| title | DprE1 inhibitors – a prospective target for development of antituberculosis drugs |
| title_full | DprE1 inhibitors – a prospective target for development of antituberculosis drugs |
| title_fullStr | DprE1 inhibitors – a prospective target for development of antituberculosis drugs |
| title_full_unstemmed | DprE1 inhibitors – a prospective target for development of antituberculosis drugs |
| title_short | DprE1 inhibitors – a prospective target for development of antituberculosis drugs |
| title_sort | dpre1 inhibitors a prospective target for development of antituberculosis drugs |
| topic | dpre1 antituberculosis drugs btz-043 pbtz-169 tba-7371 opc-167832 multiple/extensive drug resistant tuberculosis |
| url | https://www.tibl-journal.com/jour/article/view/1644 |
| work_keys_str_mv | AT avkukurika dpre1inhibitorsaprospectivetargetfordevelopmentofantituberculosisdrugs |